共 11 条
[1]
Galloway J.A., Chance R.E., Insulin agonist therapy: a challenge for the 1990s, Clin Therapeutics, 12, pp. 459-472, (1990)
[2]
Bliss M., A history of insulin, Diabetes Care, 16, pp. 4-7, (1993)
[3]
Heinemann L., Richter B., Clinical pharmacology of human insulin, Diabetes Care, 16, pp. 90-100, (1993)
[4]
Galloway J.A., New directions in drug development : mixtures, analogues, and modeling, Diabetes Care, 16, pp. 16-24, (1993)
[5]
Stramm L.E., The role of the pharmaceutical industry in implementing the DCCT recommendations, IDF Bull, 39, pp. 16-20, (1994)
[6]
Galloway J.A., Chance R.E., Su K.E., Human insulin and its modifications, pp. 23-24, (1991)
[7]
The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus, N Engl J Med, 329, pp. 977-988, (1993)
[8]
Zinman B., Insulin regimens and strategies for IDDM, Diabetes Care, 16, pp. 24-28, (1993)
[9]
Howey D.C., Bowsher R.R., Brunelle R.L., Woodworth J.R., [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin, Diabetes, 43, pp. 396-402, (1994)
[10]
Garg S.K., Carmain J.A., Braddy K.C., Jennings M.K., Chase H.P., Pre-meal insulin analog (Lys-Pro) vs human regular insulin treatment in young subjects with type I diabetes [Abstract], Diabetes, 43, (1994)